Advertisement
Advertisement

ELTX

ELTX logo

Elicio Therapeutics, Inc. Common Stock

7.63
USD
Sponsored
-0.45
-5.57%
Jan 30, 15:59 UTC -5
Closed
exchange

After-Market

7.63

0.00
0.00%

ELTX Earnings Reports

Positive Surprise Ratio

ELTX beat 8 of 18 last estimates.

44%

Next Report

Date of Next Report
Mar 30, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.45
Implied change from Q3 25 (Revenue/ EPS)
--
/
-25.00%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-55.88%

Elicio Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 13, 2025, ELTX reported earnings of -0.60 USD per share (EPS) for Q3 25, missing the estimate of -0.56 USD, resulting in a -6.95% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.20% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 analysts forecast an EPS of -0.45 USD, with revenue projected to reach -- USD, implying an decrease of -25.00% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Elicio Therapeutics, Inc. Common Stock reported EPS of -$0.60, missing estimates by -6.95%, and revenue of $0.00, 0% as expectations.
The stock price moved down -2.2%, changed from $9.11 before the earnings release to $8.91 the day after.
The next earning report is scheduled for Mar 30, 2026.
Based on 4 analysts, Elicio Therapeutics, Inc. Common Stock is expected to report EPS of -$0.45 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement